Several studies have shown that complete withdrawal of an obesity treatment dose of a GLP-1RA without other structured care leads to weight regain in most people.2 However, it remains unclear whether lifelong treatment of obesity should always consist of GLP-1RAs at full obesity dosing or whether a range of alternative strategies can enable some subset of people with obesity to maintain their weight loss after a limited duration of initial treatment, followed by tapering, discontinuing, or off-ramping these agents." This paragraph from the article, I believe, sums up nicely what this means
This is a known effect of glucagon receptor activation and is being monitored closely
The calculation was correct in Q4
injection and resulting AUC in Dpp4 EC+/+ ( n =7) and Dpp4 EC/ ( n = 6) mice
Ozempic has emerged as a significant player in the management of type 2 diabetes and, more recently, in the realm of weight loss
its a physiological reality